2025.06.10 最後審閱 2026.04.06 衛教猛健樂甲狀腺

健檢發現甲狀腺結節能減重嗎？破解 3 個用藥疑慮，一般結節患者安心使用指南

Name: 健檢發現甲狀腺結節能減重嗎？破解 3 個用藥疑慮，一般結節患者安心使用指南 - 博田國際健康管理中心
Creator: 黃柏誠醫師
Published: 2025-06-10T10:06:00+08:00
Keywords: 健檢發現甲狀腺結節能減重

一般體檢發現的良性甲狀腺結節，並不會阻礙你使用減重藥物，多項跨國大型數據皆證實其安全性。
藥物外盒的黑框警告，主要是針對非常罕見的甲狀腺髓質癌家族史，一般民眾不需過度恐慌。
在體重管理期間，維持每年一次的甲狀腺超音波定期追蹤，就能確保健康與體態雙贏。

甲狀腺結節在台灣是非常普遍的情況，許多人擔心這會成為減重路上的絆腳石。最新的大型跨國研究已經證實，只要結節是良性的，使用猛健樂這類藥物是非常安全的。醫學界嚴格限制使用的對象，其實是極少見的甲狀腺髓質癌患者。

只要配合定期追蹤，一般結節患者完全可以安心規劃體重管理療程。

王太太上週拿著體檢報告走進診間，眉頭深鎖。她原本打算諮詢最近很紅的雙重腸泌素減重療程，幫助自己擺脫產後一直降不下來的數字。沒想到報告上「甲狀腺結節」這幾個字，讓她嚇得立刻打消了念頭。

旁邊陪同的女兒也一臉擔憂，連忙問說這會不會有危險。其實甲狀腺結節在台灣非常普遍，特別是女性朋友。很多時候，這些結節就像皮膚上的痣一樣，靜靜地待在那裡，並不會對健康造成威脅。多數人都是毫無知覺地和平共處了好幾年。

想追求更輕盈的體態，同時又顧慮脖子上的小結節，兩者真的衝突嗎？我們今天就來好好聊聊，最新醫學證據到底怎麼看待這件事。那些藥物包裝盒上的黑框警告，真正要提醒的對象究竟是誰。

為什麼報告有紅字

超音波掃描發現結節，聽起來好像脖子裡長了不該長的東西。這時候大家最常問的問題就是，這些小東西到底從哪裡來的。

我們的甲狀腺就像一個小巧的蝴蝶形狀器官，位在脖子正前方。它每天辛勤工作，負責分泌賀爾蒙來調節全身的新陳代謝。

結節就像皮膚上的小肉瘤

想像一下，你的皮膚偶爾會長出一些小肉瘤或息肉。

甲狀腺結節的概念也很類似，就是甲狀腺組織局部稍微增生，形成了一個小突起。多數情況下，這些突起都是良性的，甚至一輩子都不會引起任何不舒服。

很多人都是在公司例行體檢時，意外透過超音波才發現自己有結節。它們默默存在，沒有症狀，也完全不會影響甲狀腺的正常運作。

髓質癌是罕見的惡性細胞

減重藥物仿單上常常提到的「甲狀腺髓質癌」，名字聽起來有點像，本質卻天差地遠。甲狀腺裡面除了分泌一般賀爾蒙的濾泡細胞，還有另一種叫做 C 細胞的特殊員工。

髓質癌就是這群少數的 C 細胞發生了惡性病變，這是一種非常罕見的狀況。一般的良性結節，絕大多數都是原本的濾泡細胞長出來的，這兩者走的是完全不相干的發病路線。

研究怎麼說？

既然良性結節和罕見癌症不同，那我們使用減重藥物時，到底安不安全？醫學界對這個議題做了非常多嚴謹的追蹤。

Tirzepatide (猛健樂) 上市前後，科學家緊盯著每一項數據。

他們想確認這款新藥，會不會對人類的甲狀腺帶來額外的負擔。

囓齒動物的實驗結果

這一切的擔憂，其實源自於早期的動物實驗。科學家在老鼠身上測試時，發現高劑量的藥物會讓老鼠的甲狀腺 C 細胞產生腫瘤。

看到這個結果，大家第一個念頭一定是懷疑人類用了會不會也這樣。科學家進一步研究發現，老鼠的甲狀腺細胞上，有一種特殊的接收器，數量比人類多出非常多。

這代表老鼠對這類藥物特別敏感。

目前醫學界普遍認為，這種在動物身上看到的風險，並不能直接套用在人類身上[1][2][3]。為了保險起見，各國衛生單位還是要求在藥物包裝上加上警告，特別限制有甲狀腺髓質癌家族史的人使用。

亞洲大型臨床試驗的解答

動物實驗是一回事，真實世界的人類數據才是判定標準。

在名為 SURMOUNT-CN 的大型試驗中，研究團隊針對亞洲華人體質進行了深入分析。

這項研究包含了許多本身就有良性甲狀腺結節的受試者。追蹤結果顯示，這群人使用猛健樂後，並沒有出現結節惡化或變成罕見癌症的情況[4]。

試驗過程中，確實有一位參與者被診斷出常見的甲狀腺乳突癌。經過醫療專家嚴格審查，確認這個病變和研究藥物完全沒有關聯[4]。這也再次證明，一般良性結節患者在醫師評估下使用，安全性是有充分保障的。

全球長期追蹤報告

除了單一地區的研究，全球還有多項涵蓋數千人的大型臨床試驗。從 SURPASS-1 到近期關於睡眠呼吸中止症的研究，團隊都把甲狀腺健康列為觀察重點[5][6][7][8]。

在這些龐大的數據庫裡，科學家完全沒有發現任何一例甲狀腺髓質癌的報告。

整體來看，使用藥物的人和沒有使用的人相比，甲狀腺出現異常的機率差不多，證明藥物並不會增加額外風險[4][5][6][7][8]。

藥物上市後，全球的藥物安全監控系統也持續在背景運作。最新分析顯示，目前並沒有觀察到任何因為使用該藥物，導致其他類型甲狀腺癌風險增加的異常通報[9]。

我需要進一步處理嗎？

到底誰可以安心減重，誰又需要特別避開？我們整理了一個簡單的對照表，幫你快速判斷目前的狀況。

指標狀況	建議行動	適合誰	追蹤時間
曾經或家人有甲狀腺髓質癌 (MTC)	絕對禁止使用此類藥物	罕見家族遺傳病史者	依專科醫師指示密切追蹤
有第二型多發性內分泌腫瘤症候群 (MEN 2)	絕對禁止使用此類藥物	特殊基因突變患者	定期進行全身性內分泌檢查
體檢發現一般良性甲狀腺結節	可經醫師評估後安心使用藥物	多數體檢意外發現結節的民眾	每半年至一年照一次超音波
脖子突然摸到硬塊或聲音持續沙啞	暫停用藥並盡速就醫檢查	用藥期間出現新症狀的人	立即安排門診評估

有沒有副作用或風險？

雖然醫學證據支持一般結節患者可以安心使用，但任何療程都有它需要了解的地方。我們把潛在狀況講清楚，大家執行起來也會更踏實。

使用腸泌素藥物，最常見的反應通常集中在腸胃道。你可能會覺得肚子脹脹的、偶爾有點噁心，或是排便習慣改變。這些感覺通常在身體適應幾週後就會慢慢緩解。

至於甲狀腺方面，如果你本身有結節，最怕的就是自己嚇自己。有時候體重順利減輕了，脖子上的皮下脂肪變薄，原本藏在裡面的結節摸起來會變得明顯一點。

這很容易讓人誤以為是結節變大了。

遇到這種狀況，直接安排一次超音波檢查最準確。醫生可以精準測量結節的公分數，不用每天對著鏡子窮緊張。

如果你在用藥期間發現聲音莫名沙啞，或者吞嚥時覺得喉嚨卡卡的，請多留一份心。

這些可能是甲狀腺出現變化的警訊，提早回診讓醫生用超音波確認一下總是比較放心。

醫師建議怎麼做？

有了科學數據背書，我們終於可以把專注力放回減重這件重要的事情上。

如果你同時有良性結節又想管理體重，日常生活中可以把握幾個大原則。

建立規律的追蹤習慣

良性結節最好的朋友就是超音波檢查。不管你有沒有使用減重療程，只要脖子上有結節，都建議每年安排一次例行掃描。

這就像是幫汽車做定期保養，確保一切都在掌控之中。只要結節大小和形狀穩定，你就可以繼續安心地進行你的體態管理計畫。

飲食營養要均衡

減重的過程中，吃得少不如吃得好。

很多人為了快速瘦下來，會採取極端的節食方法，這對身體的代謝反倒會造成負擔。

甲狀腺負責管理我們的新陳代謝，它需要足夠的營養才能正常工作。確保每一餐都有優質的蛋白質，搭配豐富的蔬菜，才能讓身體在減脂的同時維持健康運作。

運動習慣不能省

藥物可以幫忙控制食慾和調整體質，但肌肉量還是得靠自己練出來。適度的阻力訓練配合有氧運動，能夠有效提升身體的基礎代謝率。

當你擁有了良好的肌肉量，就算未來療程結束，也比較不容易復胖。

把運動融入生活，當作每週放鬆心情的時間，這條路才能走得長久。

常見誤解澄清

門診裡總是會聽到各種千奇百怪的網路傳言。我們挑出幾個點閱率最高的問題，一次幫大家講清楚。

良性結節放著不管，遲早會變成癌症嗎？

真相：這是不正確的觀念。良性結節和惡性腫瘤在細胞本質上就不一樣。

一個乖乖待在原地的良性肉瘤，很少會突然基因突變變成惡性腫瘤。定期的超音波追蹤，主要是為了及早發現那些一開始就長得不太友善的新病灶。

打瘦瘦筆會刺激結節吸收營養，越長越大嗎？

真相：目前沒有任何人類的臨床證據支持這個說法

各大臨床試驗長期追蹤下來，結節患者的狀況都非常穩定[4][6][8]。

如果我剛好有結節，是不是一輩子都不能碰這類藥物了？

真相：這真的是天大的誤會。

各大醫學會的指引寫得很清楚，禁忌症只有極少數的甲狀腺髓質癌和特定基因突變[1][2]。一般的良性甲狀腺結節，只要經過專業醫師評估確認，都可以安全地納入減重計畫中。

重點整理

一般體檢發現的良性甲狀腺結節，並不會阻礙你使用減重藥物，多項跨國大型數據皆證實其安全性。
藥物外盒的黑框警告，主要是針對非常罕見的甲狀腺髓質癌家族史，一般民眾不需過度恐慌。
在體重管理期間，維持每年一次的甲狀腺超音波定期追蹤，就能確保健康與體態雙贏。

English Version

Thyroid Nodule and Want to Lose Weight? Debunking 3 Medication Concerns -- A Safety Guide for Patients with Benign Nodules

Thyroid nodules are extremely common in Taiwan, and many people worry they will be a roadblock on the path to weight management. The latest large-scale multinational research confirms that as long as the nodule is benign, using medications like tirzepatide is very safe. The patients that medical guidelines strictly restrict are those with the exceedingly rare medullary thyroid carcinoma.

With regular follow-up, patients with ordinary benign nodules can confidently pursue their weight management journey.

Mrs. Wang came into the office last week clutching her health screening report, her brow deeply furrowed. She had originally planned to ask about the popular dual incretin weight-loss therapy to help shed the stubborn post-pregnancy pounds. But the words "thyroid nodule" on the report made her abandon the idea on the spot.

Her daughter, who came along, looked equally worried and immediately asked whether it could be dangerous. In fact, thyroid nodules are extremely prevalent in Taiwan, particularly among women. Most of the time, these nodules are like moles on the skin -- they sit there quietly and pose no threat to health. Many people coexist peacefully with them for years without ever knowing.

Wanting a leaner physique while also worrying about a small nodule in your neck -- do these two things really conflict? Let us have a thorough conversation today about what the latest medical evidence says and who those black-box warnings on drug packaging are actually meant for.

Why Your Report Is Flagged

Hearing that an ultrasound scan found a nodule can make it sound like something unwanted has grown in your neck. The most common question at this point is: where did these little things come from?

Our thyroid is a small, butterfly-shaped organ located at the front of the neck. It works diligently every day, secreting hormones to regulate the body's metabolism.

Nodules Are Like Skin Tags

Imagine your skin occasionally developing small skin tags or polyps. Thyroid nodules are a similar concept -- a localized area of thyroid tissue that has slightly overgrown, forming a small bump. In most cases, these bumps are benign and may never cause any discomfort throughout your entire life.

Many people discover their nodules incidentally during a routine company health screening ultrasound. The nodules exist silently, cause no symptoms, and do not affect thyroid function at all.

Medullary Carcinoma Is a Rare Malignancy

The "medullary thyroid carcinoma" frequently mentioned in weight-loss drug package inserts sounds similar in name but is worlds apart in nature. Inside the thyroid, besides the follicular cells that produce regular hormones, there is another type of specialized worker called C cells. Medullary carcinoma occurs when these rare C cells undergo malignant transformation -- an extremely uncommon event. Ordinary benign nodules overwhelmingly originate from follicular cells, following an entirely unrelated disease pathway.

What Does the Research Say?

Since benign nodules and rare cancers are different, is it actually safe to use weight-loss medications? The medical community has conducted extensive, rigorous monitoring on this question.

Before and after tirzepatide's market launch, scientists scrutinized every data point to confirm whether this new drug places any additional burden on the human thyroid.

Rodent Experiment Results

All the concern actually stems from early animal studies. When scientists tested high doses in rats, they found the drug triggered thyroid C-cell tumors. Naturally, the first thought was whether the same could happen in humans.

Further investigation revealed that rat thyroid cells carry a specific type of receptor in far greater quantities than human cells, making rats particularly sensitive to this class of drug.

The medical community generally agrees that the risk observed in animals cannot be directly applied to humans. As a precaution, regulatory agencies worldwide still require a warning on the packaging, specifically restricting use in individuals with a family history of medullary thyroid carcinoma.

Answers from a Large Asian Clinical Trial

Animal experiments are one thing; real-world human data are the true benchmark. In the large trial called SURMOUNT-CN, researchers conducted an in-depth analysis tailored to the Asian Chinese population.

This study included many participants who already had benign thyroid nodules. Follow-up results showed that after using tirzepatide, there were no cases of nodule progression or transformation into rare carcinoma.

During the trial, one participant was diagnosed with common papillary thyroid carcinoma. After rigorous expert review, the lesion was confirmed to be completely unrelated to the study drug. This further demonstrates that safety for patients with ordinary benign nodules, when used under physician evaluation, is well-supported.

Global Long-Term Surveillance Reports

Beyond regional studies, multiple large-scale clinical trials worldwide have enrolled thousands of participants. From SURPASS-1 to recent studies on obstructive sleep apnea, research teams have consistently listed thyroid health as a key observation endpoint.

Across these vast databases, scientists have found zero reports of medullary thyroid carcinoma. Overall, the rate of thyroid abnormalities among drug users was comparable to that of non-users, proving the medication does not add extra risk.

After market launch, global pharmacovigilance systems continue running in the background. The latest analysis shows no unusual reports of increased risk for any other type of thyroid cancer associated with the drug.

Do I Need Further Action?

Who can confidently proceed with weight loss, and who should exercise caution? Here is a quick reference table.

Personal or family history of medullary thyroid carcinoma (MTC): Absolutely contraindicated. Rare familial genetic condition. Follow specialist instructions for close monitoring.

Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome: Absolutely contraindicated. Specific gene mutation carriers. Regular comprehensive endocrine screening.

Benign thyroid nodule found on routine screening: May proceed with medication after physician evaluation. Most individuals with incidentally discovered nodules. Thyroid ultrasound every 6 to 12 months.

New neck lump or persistent hoarseness: Pause medication and seek medical evaluation promptly. Those developing new symptoms during therapy. Arrange a clinic visit immediately.

Are There Side Effects or Risks?

Although the evidence supports safe use for patients with ordinary nodules, every treatment has aspects worth knowing about.

The most common reactions with incretin-based medications center on the gastrointestinal tract. You may feel bloated, occasionally nauseous, or notice changes in bowel habits. These sensations usually ease as the body adapts over several weeks.

Regarding the thyroid, if you already have a nodule, the biggest trap is scaring yourself. Sometimes as weight loss succeeds and subcutaneous fat in the neck thins out, a previously hidden nodule becomes more palpable. It is easy to mistake this for the nodule growing larger.

When this happens, simply schedule an ultrasound for an accurate measurement. The doctor can measure the nodule precisely in centimeters -- no need to stand in front of the mirror worrying every day.

If you notice unexplained hoarseness or a sensation of something stuck in your throat while swallowing during therapy, pay extra attention. These could be signs of thyroid changes. An early visit to let your doctor confirm with ultrasound always provides peace of mind.

What Does Your Doctor Recommend?

With scientific data backing you up, you can finally redirect your focus to the important matter of weight management. If you have a benign nodule and also want to manage your weight, keep these daily principles in mind.

Build a Routine Follow-Up Habit

A benign nodule's best friend is the ultrasound. Whether or not you are on a weight-loss regimen, as long as you have a nodule, annual routine scanning is recommended. Think of it as regular car maintenance -- ensuring everything is under control. As long as the nodule's size and shape remain stable, you can continue your body-shaping plan with confidence.

Keep Nutrition Balanced

During weight loss, eating less matters less than eating well. Many people resort to extreme dieting for rapid results, which actually burdens the metabolism. The thyroid manages our metabolic rate and needs adequate nutrition to function properly. Make sure every meal includes quality protein paired with abundant vegetables to keep the body healthy while losing fat.

Do Not Skip Exercise

Medication can help control appetite and adjust body composition, but muscle mass must be built through your own effort. Moderate resistance training combined with aerobic exercise effectively boosts basal metabolic rate. With good muscle mass, you are much less likely to rebound after treatment ends. Weave exercise into your life as a weekly stress-relief ritual, and the journey becomes sustainable.

Clearing Up Common Misconceptions

Will a benign nodule inevitably turn into cancer if left alone?

The truth: This is incorrect. Benign nodules and malignant tumors are fundamentally different at the cellular level. A well-behaved benign lump rarely undergoes sudden genetic mutation to become malignant. Regular ultrasound monitoring is mainly to catch any new lesions that appear unfriendly from the start.

Will weight-loss injections stimulate the nodule to absorb nutrients and grow bigger?

The truth: No human clinical evidence supports this claim. Long-term follow-up across major clinical trials consistently shows that nodule status remains stable in treated patients.

If I happen to have a nodule, can I never use this class of medication?

The truth: That is a massive misunderstanding. Medical guidelines are very clear: the contraindications apply only to the extremely rare medullary thyroid carcinoma and specific gene mutations. Ordinary benign thyroid nodules, once confirmed by professional medical evaluation, can be safely incorporated into a weight management plan.

Key Takeaways

Benign thyroid nodules found on routine screening do not prevent you from using weight-loss medications -- multiple multinational large-scale datasets confirm their safety.

The black-box warning on drug packaging is primarily aimed at the very rare medullary thyroid carcinoma family history; the general public need not overreact.

During weight management, maintaining an annual thyroid ultrasound follow-up ensures you achieve both health and a better physique.

參考文獻

Apovian CM, Aronne L, Barenbaum SR. Clinical Management of Obesity – Third Edition. The Obesity Society. 2025;
Coppenrath V, Mazyck B. Tirzepatide (Zepbound) for the Treatment of Obesity. American Family Physician. 2024;110(2):199-200.
Rebitch CB. Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus. American Family Physician. 2023;108(1):93-94.
Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024;332(7):551-560. DOI: 10.1001/jama.2024.9217
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England Journal of Medicine. 2025;392(10):958-971. DOI: 10.1056/NEJMoa2410819
Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England Journal of Medicine. 2024;391(13):1193-1205. DOI: 10.1056/NEJMoa2404881
Rosenstock J, Wysham C, Frías JP, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. Lancet (London, England). 2021;398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6
Caruso I, Di Gioia L, Di Molfetta S, et al. The Real-World Safety Profile of Tirzepatide: Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Journal of Endocrinological Investigation. 2024;47(11):2671-2678. DOI: 10.1007/s40618-024-02441-z

猛健樂完整指南

想了解更多關於 Tirzepatide（猛健樂）的使用資格、禁忌症與注意事項？

請閱讀我們的完整指南：

減重針劑不是人人能打！搞懂 3 個關鍵門檻與禁忌，醫師教你正確評估

黃柏誠醫師

✓ 認證作者衛福部醫事人員

博田國際健康管理中心醫療主任、家庭醫學專科醫師。台灣大學醫學系醫學士、高雄醫學大學藥學碩士、美國哈佛 BIDMC 老年醫學科訪問醫師、體適能健身 C 級指導員認證。專長預防醫學與減重醫學，擅長以資訊工具優化臨床流程。

醫療免責聲明

本文內容僅供衛教參考，不構成個人醫療建議、診斷或治療方案。任何健康問題請諮詢您的主治醫師或合格醫療專業人員。博田國際健康管理中心對依據本文內容所做之決定不承擔任何責任。

最後審閱日期：2026 年 4 月 6 日

搜尋

熱門關鍵字

健檢發現甲狀腺結節能減重嗎？破解 3 個用藥疑慮，一般結節患者安心使用指南

為什麼報告有紅字

結節就像皮膚上的小肉瘤

髓質癌是罕見的惡性細胞

研究怎麼說？

囓齒動物的實驗結果

亞洲大型臨床試驗的解答

全球長期追蹤報告

我需要進一步處理嗎？

有沒有副作用或風險？

醫師建議怎麼做？

建立規律的追蹤習慣

飲食營養要均衡

運動習慣不能省

常見誤解澄清

重點整理

參考文獻

猛健樂完整指南

黃柏誠醫師

搜尋

熱門關鍵字

健檢發現甲狀腺結節能減重嗎？破解 3 個用藥疑慮，一般結節患者安心使用指南

為什麼報告有紅字

結節就像皮膚上的小肉瘤

髓質癌是罕見的惡性細胞

研究怎麼說？

囓齒動物的實驗結果

亞洲大型臨床試驗的解答

全球長期追蹤報告

我需要進一步處理嗎？

有沒有副作用或風險？

醫師建議怎麼做？

建立規律的追蹤習慣

飲食營養要均衡

運動習慣不能省

常見誤解澄清

重點整理

參考文獻

猛健樂完整指南

黃柏誠醫師

其他健康專欄